Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical technology market

This article was originally published in The Gray Sheet

Executive Summary

Study on "the state of the medical technology industry" kicks off the week of Dec. 16 with the mailing of a comprehensive survey to roughly 800 manufacturers, the Health Industry Manufacturers Association announces Dec. 16. Conducted by the Lewin Group, the study will examine changes in the market environment over the past five years and address new barriers to obtaining reimbursement (1"The Gray Sheet" Nov. 1, p. 5). HIMA expects to issue the first study report, on "the health care market and regulatory environment," in early 2000

You may also be interested in...



HIMA Device Industry Strategic Study Update Expected In January 2000

A Health Industry Manufacturers Association-sponsored study scheduled to commence sometime in January will focus on the state of the medical device sector and the impact of Medicare regulations on patient access to medical devices since 1995.

AAM Welcomes Proposal To Update Medicare Part D

After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.

Dr Reddy’s Wants To Break Into Top Five In India

Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel